TriSalus Life Sciences, Inc.
TLSINASDAQHealthcare● Active
$3.21
+$0.04(+1.26%)
Market Cap$121691610
P/E Ratio—
52W High$7.95
52W Low$2.2
TriSalus Life Sciences, Inc. (TLSI) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TLSI · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $45.15M | $29.43M | $18.51M | $12.40M | $8.40M |
| Cost of Revenue | $6.96M | $4.10M | $2.60M | $2.26M | $1.19M |
| Gross Profit | $38.19M | $25.33M | $15.91M | $10.14M | $7.21M |
| Gross Margin %(computed) | 84.57% | 86.06% | 85.93% | 81.79% | 85.80% |
| Operating Expenses | |||||
| R&D Expenses | $14.96M | $17.69M | $29.84M | $21.36M | $14.22M |
| G&A Expenses | $21.46M | $17.97M | $23.51M | $12.48M | $8.75M |
| Total Operating Expenses | $65.13M | $61.49M | $70.38M | $46.58M | $31.24M |
| Operating Income | ($26.95M) | ($36.16M) | ($54.48M) | ($36.44M) | ($24.03M) |
| Operating Margin %(computed) | -59.68% | -122.88% | -294.28% | -293.91% | -286.06% |
| Interest Income | $0.56M | $0.40M | $0.43M | $0.18M | $0.00M |
| Interest Expense | $5.54M | $3.09M | $0.02M | $0.00M | $1.76M |
| Income Before Tax | ($39.22M) | ($30.04M) | ($59.35M) | ($47.18M) | ($28.84M) |
| Income Tax Expense | $0.01M | $0.01M | $0.01M | $0.01M | $0.00M |
| Net Income | ($39.23M) | ($33.23M) | ($59.36M) | ($47.19M) | ($28.84M) |
| Net Margin %(computed) | -86.88% | -112.92% | -320.69% | -380.60% | -343.35% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.84 | $-1.25 | $-2.23 | $-1.59 | $-0.92 |
| Wtd Avg Shares | 49.19M | 26.50M | 26.47M | 29.61M | 31.25M |
| EBITDA | ($26.95M) | ($36.16M) | ($58.65M) | ($46.76M) | ($23.57M) |
| EBITDA Margin %(computed) | -59.68% | -122.88% | -316.86% | -377.18% | -280.54% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more TriSalus Life Sciences, Inc. data
About TriSalus Life Sciences, Inc. (TLSI) Income Statement
TriSalus Life Sciences, Inc. (TLSI) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, TLSI reported revenue of $0.05B, gross profit of $0.04B (gross margin 84.57%), and net income of ($0.04B) — a net profit margin of -86.88%.
Frequently asked questions
TLSI · 4 questionsTriSalus Life Sciences, Inc. (TLSI) reported revenue of $0.05B for 2025, up 53.4% year-over-year.
TLSI revenueTLSI salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08